Biological therapies in Crohn’s disease: are they cost-effective? A critical appraisal of model-based analyses
Author:
Publisher
Informa UK Limited
Subject
Pharmacology (medical),Health Policy,General Medicine
Link
http://www.tandfonline.com/doi/pdf/10.1586/14737167.2014.957682
Reference54 articles.
1. American Gastroenterological Association Institute Guideline on the Use of Thiopurines, Methotrexate, and Anti–TNF-α Biologic Drugs for the Induction and Maintenance of Remission in Inflammatory Crohn's Disease
2. The Italian Society of Gastroenterology (SIGE) and the Italian Group for the study of Inflammatory Bowel Disease (IG-IBD) Clinical Practice Guidelines: The use of tumor necrosis factor-alpha antagonist therapy in Inflammatory Bowel Disease☆
3. The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management
4. Meta-analysis/Systematic review Tumor necrosis factor-α antibodies (infliximab, adalimumab and certolizumab) in Crohn's disease: systematic review and meta-analysis
5. American Gastroenterological Association Institute Technical Review on the Use of Thiopurines, Methotrexate, and Anti–TNF-α Biologic Drugs for the Induction and Maintenance of Remission in Inflammatory Crohn's Disease
Cited by 30 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Global burden of inflammatory bowel disease 1990-2019: A systematic examination of the disease burden and twenty-year forecast;World Journal of Gastroenterology;2023-11-14
2. Global burden of inflammatory bowel disease 1990-2019: A systematic examination of the disease burden and twenty-year forecast;World Journal of Gastroenterology;2023-11-14
3. Early Flexible Sigmoidoscopy Improves Clinical Outcomes in Acute Severe Ulcerative Colitis;Crohn's & Colitis 360;2023-05-31
4. The cost of inflammatory bowel disease in high-income settings: a Lancet Gastroenterology & Hepatology Commission;The Lancet Gastroenterology & Hepatology;2023-05
5. Global, regional and national burden of inflammatory bowel disease in 204 countries and territories from 1990 to 2019: a systematic analysis based on the Global Burden of Disease Study 2019;BMJ Open;2023-03
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3